HALO logo

HALOHalozyme Therapeutics Inc.

$66.25
$1.89
(2.77%)
Today
Updated: 01:14 PM EDT
Reported EarningsMay 11
Mkt Cap$8.08B
Vol704,003.00
News
all
press releases
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Zacks
News Placeholder
More News
News Placeholder
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Zacks
News Placeholder
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Zacks
News Placeholder
Company News for May 13, 2026
Companies In The News Are: SPG, HIMS, NOVT, HALO.
Zacks
News Placeholder
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Zacks
News Placeholder
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
News Placeholder
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE PR Newswire SAN DIEGO, May 11, 2026 Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in...
PR Newswire
News Placeholder
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>